Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
Polymer OLED Devices
European partners collaborate in ′development of replacement of ITO for OLEDs
Polymer OLED Devices : 20 September, 2014
Currently the commercialisation of Organic Light Emitting Diode (OLED) and Organic Photovoltaic (OPV) based applications such as flexible displays, lighting and energy harvesting devices is heavily dependent on the use of indium tin oxide (ITO) for transparent conducting films, and encapsulation films with high performance barrier properties. There is an industry need for the creation of alternative technologies and materials that have equal performance but deliver low cost, sustainable, transparent and flexible products for these applications. Throughout Europe, it is proving extremely difficult to develop the manufacture of these alternative materials beyond laboratory scale to the position where they are available in large area quantities at a price compatible with supporting market growth.
 
Ultra-flexible OTFT device array suitable for the foldable AMOLED displays of the future
Polymer OLED Devices : 27 January, 2014
The Centre for Process Innovation (CPI), the UK’s National Centre for Printable Electronics. has developed novel backplane fabrication processes to allow the bending of Organic Thin Film Transistors (OTFT) arrays to small radii (c.1mm) without a significant reduction in device performance. The work undertaken demonstrates progress towards optimum Organic Semiconductor (OSC)/OTFT processing and performance to enable their integration into ultra-flexible active matrix organic light emitting diode AMOLED backplanes.
 
Platinum-doped polymer emits brighter, whiter, light
Polymer OLED Devices : 14 October, 2013
By inserting platinum (Pt) atoms into an organic semiconductor, a group at the University of Utah has tuned the polymer to emit light of different colours - a step towards truly white organic LEDs (OLEDs) for lighting. Existing white-emitting OLEDs use other techniques for white output, such as combining a blue OLED with a yellow phosphor.
 
Positive Phase II data on TRX4 (ChAglyCD3)
Polymer OLED Devices : 13 May, 2007
BTG plc, the medical innovations company, notes that TolerRx, Inc., BTG
 
BTG licenses haemofiltration device patents to Fresenius Medical Care
Polymer OLED Devices : 22 April, 2007
BTG plc, the medical innovations company, announces that it has granted Fresenius Medical Care AG & Co. KGaA a non-exclusive licence for the global rights to patents relating to a haemofiltration device for
 
New CP-141, a novel modified oral formulation of a product used for the treatment of asthma
Polymer OLED Devices : 21 April, 2007
BTG, the medical innovations company, announced today that it has entered into a Collaboration Agreement with Collegium Pharmaceutical, Inc., a specialty product development company, to develop CP-141, a novel modified oral formulation of a product used for the treatment of asthma.
 
BTG licenses analgesic compounds from Asterand
Polymer OLED Devices : 20 April, 2007
BTG plc, the medical innovations company, and Asterand plc (formerly Pharmagene plc) announce that the companies have entered into an exclusive licence agreement, whereby BTG acquires the rights to a series of compounds discovered and developed by Asterand to treat painful conditions such as migraine headache.
 
BTG completes sale of RFID patent portfolio
Polymer OLED Devices : 19 April, 2007
BTG plc, the medical innovations company, today announces that Zebra Technologies Corporation has exercised its option to acquire the remainder of BTG's radio frequency identification patent portfolio for $3.8 million gross.
 
Strata Technology partners retained by BTG to auction rights to a substantial OLED patent portfolio
Polymer OLED Devices : 18 April, 2007
Strata Technology Partners, the London-based corporate finance advisory firm, announced today that it has been retained by BTG plc to auction the control over a substantial OLED patent portfolio via an exclusive license with prosecution, sublicensing and litigation rights in the field of information displays.
 
Study met primary endpoint of progression free survival with Campath
Polymer OLED Devices : 17 April, 2007
Genzyme Corporation and Berlex Inc., a U.S. affiliate of Schering AG, Germany, majority-owned by the Bayer Group, today announced results from CAM307, an international Phase III clinical trial comparing Campath (alemtuzumab) with chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukemia. The study data were presented at the 48th Annual Meeting of the American Society of Hematology in Orlando.
 
Genzyme reports Phase III data showing Campath is superior to Chlorambucil as a first-line therapy in B-CLL
Polymer OLED Devices : 16 April, 2007
BTG plc, the medical innovations company, notes that its licensee Genzyme Corporation has published positive results from a Phase III study comparing Campath with Chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukaemia. An extract from the announcement follows.
 
European phase III randomised controlled trial comparing Varisolve with surgery or sclerotherapy
Polymer OLED Devices : 15 April, 2007
BTG plc, the medical innovations company, announces that the full results of the Phase III European trial of Varisolve, the novel microfoam treatment for varicose veins, have been published in the journal Phlebology 1, confirming the non-inferiority of Varisolve to the alternative treatments.
 
New scientific research shows low-level supplements of Potassium to normal diet can lower blood pressure
Polymer OLED Devices : 03 November, 2006
Data published in July edition of British Journal of Nutrition from King
 
BTG licensee TolerRx, Inc. raises $35.6m to develop TRX4; Phase III pivotal trial in type 1 diabetes
Polymer OLED Devices : 03 November, 2006
BTG plc, the medical innovations company, today announces that TolerRx, Inc. has raised $35.6 million to advance the development of TRX4 as a treatment for type 1 diabetes and plans to commence a Phase III pivotal trial in 2006. TolerRx, BTG's exclusive licensee for the anti-CD3 monoclonal antibody TRX4, is also developing TRX4 as a treatment for psoriasis.
 
New surgical sealant technology from BTG
Polymer OLED Devices : 15 October, 2006
BTG, the global technology commercialisation company, announced today it will commercialise the rights to a new surgical sealant technology, which could replace traditional suturing in surgery, as well as provide advantages over biochemical sealants currently in use.
 
MCA approves pivotal Phase III trials for Varisolve in the UK
Polymer OLED Devices : 15 October, 2006
BTG plc announced that its wholly owned subsidiary, Provensis Ltd, has received a letter of approval from the Medicines Controls Agency for its Clinical Trials Exemption confirming that the Phase III study for its Varisolve procedure can go ahead in the UK.
 
New tamoxifen formulation shown to substantially retard growth of resistant tumors
Polymer OLED Devices : 14 October, 2006
Scientists have discovered a new formulation of tamoxifen which can treat breast cancers that are resistant to the standard formulation of the drug. Tamoxifen is the most widely prescribed breast cancer medicine in the world. BTG, the global technology commercialisation company, is now working to develop and commercialise liposomal tamoxifen, this new drug.
 
New drug to treat chronic lymphocytic leukaemia likely to go on sale by end of the year
Polymer OLED Devices : 14 October, 2006
BTG, the global technology commercialisation company, announced today that the U.S. Food & Drug Administration has granted accelerated approval of Campath (alemtuzumab) humanised monoclonal antibody for use as a treatment for patients with B-cell chronic lymphocytic leukaemia who have been treated with alkylating agents and have failed fludarabine therapy.
 
BTG launches company to develop breakthrough technology to treat broad array of neurological conditions
Polymer OLED Devices : 13 October, 2006
London, UK: BTG, the global technology commercialisation company, today launched KetoCytonyx, Inc., a company created to develop BTG
 
BTG reports positive results from UK Varisolve trials
Polymer OLED Devices : 13 October, 2006
BTG, the global technology commercialisation company, today announced that its wholly owned subsidiary, Provensis, reported findings from the independent physician-led trials of Varisolve, the new microfoam treatment for varicose veins. Two pilot studies were conducted in Aberdeen and Manchester and both demonstrated the treatment to be safe and effective.
 
BTG licences the electro-absorption modulator technology
Polymer OLED Devices : 12 October, 2006
BTG, the global technology commercialisation company, today announced it has signed licensing agreements with Oki Electric Industry Co. Ltd., a telecommunications manufacturer, and NTT Electronics Corporation, a worldwide supplier of high performance opto-electronic products, for the Electro-Absorption Modulator technology.
 
BTG announces X-MatchPROVW licensing opportunity
Polymer OLED Devices : 12 October, 2006
BTG, a global leader in commercialising technology, is seeking companies interested in licensing X-MatchPROVW, the next generation of the X-MatchPRO technologies originally commercialised by BTG. X-MatchPROVW is a fully verified, lossless compression technology that enables companies to realise significant savings in time and money, by quickly and easily doubling both the bandwidth of their data transmission lines and the capacity of their storage networks.
 
New technology with potential for real-time detection of anthrax and other infectious diseases
Polymer OLED Devices : 11 October, 2006
BTG, the global technology commercialisation company, today announced it has acquired a new diagnostic technology that has the potential to offer real-time detection of infectious diseases, such as anthrax, smallpox, AIDS and influenza. The primary application for the fibre optic based sensor is in the point-of-care medical market, but it can also be incorporated into environmental monitoring systems to detect airborne diseases.
 
BTG initiates Phase I trial of AQ4N, an innovative cancer drug
Polymer OLED Devices : 11 October, 2006
BTG, a global leader in commercialising innovative technologies, announced today the start of a Phase I clinical study to test AQ4N, a new drug designed to increase the effectiveness of several widely-used anticancer drugs as well as radiotherapy.
 
New drug application filed for BTG's Oxycodone HCl/Ibuprofen technology
Polymer OLED Devices : 10 October, 2006
BTG, the global technology commercialisation company, announced today that Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, has submitted a New Drug Application with the U.S.
 
BTG acquires innovative compounds for use in treating cardiac and renal disease
Polymer OLED Devices : 10 October, 2006
BTG, the global technology commercialisation company, has obtained exclusive rights from Genentech, Inc. to develop and commercialise an Atrial Natriuretic Factor peptide technology, shown to have therapeutic potential in treating acute congestive heart failure, acute renal failure and renal hypertension. BTG is seeking to license this technology.
 
BTG and ISREC release new data supporting use of Adenoviral Treatment for Colorectal Cancer
Polymer OLED Devices : 09 October, 2006
BTG, the global technology commercialisation company, and the Swiss Institute for Experimental Cancer Research released data that supports the development of a new approach to treat colorectal cancer. As demonstrated in their in vitro studies published in the current issue of Gene Therapy, researchers exploited a genetic defect commonly found in colorectal cancer cells to engineer a virus that selectively replicates within and destroys these tumour cells.
 
Leading scientists join BTG network to explore potential of nanotechnology
Polymer OLED Devices : 09 October, 2006
BTG, the global technology commercialisation company, today launched the BTG Nanotechnology Network, a think-tank of leading international scientists working in the fields of nanotechnology.
 
Leading scientists join BTG network to explore potential of nanotechnology
Polymer OLED Devices : 09 October, 2006
BTG, the global technology commercialisation company, today launched the BTG Nanotechnology Network, a think-tank of leading international scientists working in the fields of nanotechnology.
 
Collaboration to jointly develop to commercialise a light-emitting polymer technology for flexible displays
Polymer OLED Devices : 08 October, 2006
BTG, the global technology commercialisation company, today announced a collaboration agreement with Taiwan's Union Chemical Laboratories of the Industrial Technology Research Institute to jointly develop and to commercialise a patented light-emitting polymer technology for flexible organic/polymer light-emitting diode information displays.
 
BTG collaborates with INO to develop photonic technology
Polymer OLED Devices : 08 October, 2006
BTG, the global technology commercialisation company, today announced that it has signed a strategic alliance agreement with INO, Canada
 
Breakthrough products eliminate bandwidth & cost barriers enabling delivery of high quality video
Polymer OLED Devices : 08 October, 2006
BTG, the global technology commercialisation company, today announced it will market a portfolio of MPEG-compatible video distribution products developed by Digital Interactive Streams, Inc. (DiStream) that will enable the delivery of near DVD quality digital video at 1 Mbps over existing telephone and cable networks with unprecedented security measures.
 
Multicarrier power amplification technology projected to save GSM providers up to $30 million per network
Polymer OLED Devices : 08 October, 2006
BTG, the global technology commercialisation company, today announced its acquisition of a new multi-branch feed-forward technology, from Simon Fraser University in Vancouver, Canada. Global Systems for Mobile Communications network operators, who are currently using single carrier power amplifiers, will now be able to take advantage of the benefits of using multicarrier power amplifiers.
 
BTG licenses new class ofpPsychiatric drugs to Abiogen Pharma S.p.A
Polymer OLED Devices : 07 October, 2006
BTG, the global technology commercialisation company, today announced it has exclusively licensed to Abiogen Pharma S.p.A the worldwide intellectual property rights to two compounds with the potential to treat anxiety and depression.
 
Senexis to develop novel treatments for ageing-related diseases
Polymer OLED Devices : 07 October, 2006
BTG plc, the global technology commercialisation company, today announced an investment in Senexis Limited, a new biotechnology company focusing on the development of pharmaceuticals for the diagnosis and treatment of ageing-related diseases caused by a common pathogenic process called amyloidosis. Senexis Limited has raised
 
BTG successfully defends key patent for GSM and 3G value added services
Polymer OLED Devices : 07 October, 2006
BTG, the global technology commercialisation company, today announced the decision by the European Patent Office to uphold its patent relating to GSM, GPRS and 3G mobile communications. The Patent had been opposed by leading SIM Card manufacturers, following its grant in 1998.
 
PMS 601 provides novel approach to fighting HIV with potential to improve effects of other existing therapies
Polymer OLED Devices : 07 October, 2006
BTG, the global technology commercialisation company, has acquired a new class of drug candidates, discovered in France, that are targeted to treat advanced and chronic HIV infection.
 
Collaboration to Assist Intellectual Property Owners in Realising Hidden Value of Patents
Polymer OLED Devices : 06 October, 2006
BTG plc, the global technology commercialisation company, today announced a collaboration with Semiconductor Insights, the leader in technical and patent analyses of integrated circuits and structures, to help semiconductor intellectual property owners maximise the return on their investments.
 
Technology developed at Cincinnati Children's and Licensed to BTG to significantly benefit adults
Polymer OLED Devices : 06 October, 2006
Cincinnati Children
 
BTG plc: Provensis receives FDA approval to commence pilot study with Varisolve
Polymer OLED Devices : 06 October, 2006
BTG plc, the global technology commercialisation company, today announced that its subsidiary Provensis Ltd has gained approval from the Food & Drug Administration to commence the first stage of a pilot study in patients in the US with Varisolve, the non-invasive procedure being developed to treat varicose veins.
 
New approach to drug delivery through bioadhesive ophthalmic drug ;INSERT
Polymer OLED Devices : 06 October, 2006
BTG, the global technology commercialisation company, today announced it had strengthened its portfolio of ophthalmic technologies with the acquisition of a new drug delivery innovation from the French veterinary pharmaceutical laboratory V
 
VARISOLVE shown similar in efficacy to, and with significant potential advantages over, existing treatments
Polymer OLED Devices : 05 October, 2006
BTG plc, the global technology commercialisation company, today announced the preliminary results of a pivotal European Phase III trial of the VARISOLVE endovenous microfoam procedure, being developed by its subsidiary Provensis Ltd as a new treatment for varicose veins.
 
BTG signs agreement with Atmel to collaborate in design & manufacture of radio frequency
Polymer OLED Devices : 05 October, 2006
BTG, the global technology commercialisation company, has announced that it has signed (in association with its RFID Venture Company, RFIP Solutions) a co-operation agreement for a UHF RFID ISO 18000-6 type chip with Atmel Corporation, a global leader in the design and manufacture of advanced logic, mixed-signal, non-volatile memory and RF semiconductors. The two companies will work together to bring added value to UHF RFID tags and systems.
 
New gene technology shown to enable production of industrial oils from a wider range of oil-seed crops
Polymer OLED Devices : 05 October, 2006
BTG , the global technology commercialisation company, today announced it will commercialise a new gene modification technology that uses a naturally-occurring plant gene to produce commercially valuable oils in soybean and other oil-seed crops. Developed at the University of British Columbia, the technology modifies the fatty acid composition of plants, which provides a higher percentage of oil suitable for industrial applications.
 
Diagnostic technology featured in Clinical Chemistry uses serum from maternal whole blood
Polymer OLED Devices : 05 October, 2006
BTG, the global technology commercialisation company, announced the issuance of U.S. Patent No. 6,258,540 covering its non-invasive method to evaluate foetal DNA in maternal blood samples. This technology has been demonstrated to accurately identify several inherited disorders, such as Down
 
Venture Fund to link Boston-Toronto-Montreal in Life Sciences Partnership
Polymer OLED Devices : 04 October, 2006
VIMAC Ventures LLC, RBC Technology Ventures Inc., and BTG are pleased to announce the commencement of VIMAC Milestone Medica Fund, an early stage life sciences fund. VMM is the latest in VIMAC Ventures
 
BTG & Cohen Marketing Services announce new way to add a Healthy Kick to snack foods & baked goods
Polymer OLED Devices : 04 October, 2006
BTG, the global technology commercialisation company, and Cohen Marketing Services today announced an agreement allowing BTG to commercialise a technology that enables higher soy content in several food product categories, including baked goods, snack foods (chips, cookies), and any other dough-based speciality foods.
 
BTG licenses two-part hip cup patents to Wright Medical Technology, Inc.
Polymer OLED Devices : 04 October, 2006
BTG, the global technology commercialisation company, today announced it has successfully licensed the two-part hip cup patents for a license fee and future royalty payments to Wright Medical Technology, Inc., a world wide designer, manufacturer and distributor of orthopaedic implants and instruments.
 
Biological compound could provide basis for broad-spectrum HIV treatment.
Polymer OLED Devices : 04 October, 2006
BTG, the global technology commercialisation company, announced today that it has acquired an important new human HIV antibody technology from researchers at BioClonetics. The antibody, identified as Clone 3, represents only the fifth human antibody worldwide with known anti-HIV potential. It has been demonstrated in in vitro tests to neutralise several clinical/primary strains of HIV virus.
 
Compounds to be developed for selected inflammatory diseases
Polymer OLED Devices : 03 October, 2006
BTG, the global technology commercialisation company, announced today that it is seeking partners to develop and commercialise its PDE-4 inhibitor portfolio for specific inflammatory indications outside of respiratory disease.
 
First | Prev  | 1 | 2 | 3  | Next  | Last
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo